Inflammatory Bowel Disease

Discussing the latest advances in Crohn’s disease and ulcerative colitis

Share this:
May 6, 2014

Adverse Perinatal Outcomes and IBD

By Margaret Shepard, Communications Specialist

Sunanda Kane, M. D., discusses a recent scientific paper published in the Journal of Perinatology about adverse perinatal outcomes for women who have IBD and are pregnant. The findings are consistent with previously done research in IBD.

Obstetricians from Kaiser Permanente in California were able to study a large number of patients in their population and compare outcomes in pregnancies of mother who had either ulcerative colitis or Crohn's disease with mothers who didn't. The researchers examined the patients over a twelve year time frame. The study didn't account for certain medicines like Remicade or Humira but did look at other common therapies used for inflammatory bowel disease (IBD), including steroids.

The results showed that women who have IBD were more likely to give birth to a child that was small for gestational age or was preterm. They didn't find any increased risk for children having birth defects, infections, or any kind of childhood cancers up to the point they finished the study. An interesting finding from the study was that the risk for the shown results was more likely in ulcerative colitis patients than Crohn's disease patients. Up until now, doctors thought Crohn's disease patients were more likely to have complications during pregnancy but researchers aren't sure that's the truth anymore.

None of these outcomes are new data. They are the same outcomes researchers in the gastroenterology literature have been talking about and are not associated with increased risk for birth defects, spontaneous abortion, or still births.

Read the full article online here.

For more information on IBD, visit

Dr. Kane is a gastroenterologist at Mayo Clinic.

Tags: Crohn's disease, gestational age, IBD, perinatal outcomes, preterm, Study Findings, Sunanda Kane, ulcerative colitis

Please login or register to post a reply.
Contact Us · Privacy Policy